3Verheust C, Goossens M, Pauwels K, et al. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination[J]. Vaccine, 2012,30(16):2623-2632.
4Viner K M,Girgis N,Kwak H,et al. B5-deficient vac- cinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals[J]. Virolo- gy, 2007,361 (2) : 356-363.
5Lederman E, Miramontes R, Openshaw J, et al. Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee:An investigation of po- tential fomites in the home environ-ment[J]. Vaccine, 2009,27(3) :375-377.
6Wollenberg A,Engler R. Smallpox, vaccination and ad- verse reactions to smallpox vaccine[J]. Curr Opin Al- lergy Clin Immunol, 2004,4 (4) : 271-275.
7Eckart R E,Love S S, Atwood J E, et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination[J]. J Am Coil Cardiol, 2004,44 (1) :201-205.
8Kemper A R,Davis M M,Freed G L. Expected adverse events in a mass smallpox vaccination campaign[J]. Eff Clin Pract,2002,5(2) :84-90.
9Casey C G,Iskander J K,Roper M H,et al. Adverse e- vents associated with smallpox vaccination in the Unit- ed States,January-October 2003[J]. JAMA, 2005,294 (21) :734-743.
10Pastoret P P,Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies: a link between Jenner and Pasteur [J]. Epidemiol Infect, 1996,116 : 235-240.
